Sekar Kathiresan, Verve CEO
Gene editing for heart disease: Verve kicks off landmark base editing trial
Verve Therapeutics has dosed the first patient with its lead cardiovascular drug, marking a major milestone for the next-gen gene editing technique known as base …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.